Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Woyach on When to Initiate Subsequent Therapy in Patients With CLL

September 23rd 2025

Jennifer A. Woyach, MD, discusses when to initiate subsequent therapy in patients with CLL.

Dr Jerkeman on Symptom Identification for Earlier MCL Diagnosis

September 23rd 2025

Mats Jerkeman, MD, discusses essential symptoms of MCL warranting referral for earlier diagnosis.

Dr Chase on the Importance of Endometrial Cancer Awareness Month

September 23rd 2025

Dana M. Chase, MD, expands on the importance of endometrial cancer awareness month, which is observed annually in September.

Spotlighting Disease Prevention Efforts Alongside Treatment Breakthroughs Is Crucial for Endometrial Cancer Risk Reduction

September 23rd 2025

Brian Slomovitz, MD, spotlights key advancements in disease management and prevention during Gynecologic Cancer Awareness Month.

Dr Dean on the Role for Pirtobrutinib in Second-Line CLL

September 23rd 2025

Asad Dean, MD, discusses the role of pirtobrutinib in second-line CLL.

Dr Slomovitz on the Importance of Education on Disease Management and Prevention During Gynecologic Cancer Awareness Month

September 23rd 2025

Brian Slomovitz, MD, discusses the importance of education, prevention, and research in the context of gynecologic cancer awareness month.

Dr Tolaney on the Potential Role for Sac-TMT With/Without Pembrolizumab in HR+, HER2– Breast Cancer

September 22nd 2025

Sara M. Tolaney, MD, MPH, discusses the potential role of Sac-TMT with/without pembrolizumab in HR+, HER2– breast cancer.

Real-World Data Show Hematologic Responses With Pacritinib in Myelofibrosis With Anemia

September 22nd 2025

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Vorasidenib Nets European Approval in IDH1/2-Mutated Grade 2 Glioma

September 22nd 2025

Vorasidenib has been approved by the European Commission for IDH1/2-mutated grade 2 glioma.

Giredestrant Plus Everolimus Meets Coprimary PFS End Points in Post–CDK Inhibitor ER+/HER2– Breast Cancer

September 22nd 2025

Giredestrant plus everolimus improved PFS vs SOC endocrine therapy plus everolimus in CDK4/6 inhibitor–pretreated, ER-positive breast cancer.

Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma

September 20th 2025

Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.

Dr Farolfi on a Real-World Study of Bevacizumab Plus SOC Therapy in Cervical Cancer

September 19th 2025

Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.

Dr Gill on a Survey of Patient Experiences and Involvement in Decision-Making in CRC

September 19th 2025

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses patient experiences and involvement in decision-making in CRC.

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma

September 19th 2025

Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.

Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma

September 19th 2025

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Taletrectinib Wins Japanese Approval for ROS1+ Advanced NSCLC

September 19th 2025

Taletrectinib was approved in Japan for advanced non–small cell lung cancer harboring ROS1 fusions.

Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications

September 19th 2025

The EMA’s CHMP has recommended the approval of subcutaneous pembrolizumab across all indications and perioperative pembrolizumab in locally advanced HNSCC.

Orca-T Delivers Major Gains Beyond Conventional Prophylaxis in Hematologic Malignancies

September 19th 2025

David Miklos, MD, PhD, discusses the potential role for Orca-T vs standard PTCy after allogeneic transplant in hematologic malignancies.

Dr Durm on Perioperative Treatment Strategies in Early-Stage NSCLC

September 18th 2025

Greg Durm, MD, discusses factors that influence his decision to utilize perioperative treatment in patients with early-stage NSCLC.

Dr Weinberg on the Rationale for Combining BXCL701 With Pembrolizumab in mPDAC

September 18th 2025

Benjamin A. Weinberg, MD, discusses the rationale for examining BXCL701 plus pembrolizumab in mPDAC.